The UK biotech industry unanimously applauded British biotechnology companies Arakis and Vectura Group when they signed the fourth largest European licensing deal with Swiss pharmaceutical company Novartis. What promise does AD 237 hold, however, and how well will Novartis compete against key players in the chronic obstructive pulmonary disease field?